CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双打击与双表达淋巴瘤：CD19 靶向 CAR-T 细胞治疗生存结局的多中心分析
英文原题：Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.
查看英文原题
Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
双打击（DHL）和双表达（DEL）DLBCL 接受标准治疗后预后不佳，但 CAR-T 可能克服这一不良预后影响。在这项多中心回顾性研究中，研究者旨在通过评估接受 CAR-T 治疗的复发/难治性 DHL 和 DEL 患者生存结局，确认这一观察，并评估 CAR-T 后复发患者的结局。研究根据 DHL 和 DEL 状态可获得性，纳入来自 13 家学术中心的 408 例成人复发/难治性 DLBCL 患者。全部 408 例纳入 DHL（n = 80）与非 DHL（n = 328）分析；其中 333 例纳入 DHL（n = 80）、DEL（n = 74）和非 DHL/DEL（n = 179）比较。多变量分析中，DHL 与非 DHL 的 PFS 无差异（HR 0.8，95% CI 0.5–1.3，p = 0.35），DHL、DEL 和其他组间也无差异（三组比较 p = 0.5）。各组缓解率和毒性相似。DEL 患者 CAR-T 后复发率最高，而 DHL 患者 CAR-T 后复发的总生存期最差。
总之，数据支持 CAR-T 可在复发/难治性治疗场景中克服 DHL 和 DEL DLBCL 的不良预后影响。此外，CAR-T 后复发的 DHL 患者预后非常差。
展开英文摘要原文
Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL.
All 408 patients were included in the DHL (n = 80) vs non-DHL (n = 328) analysis, while 333 patients were included in the analysis of DHL (n = 80) vs DEL (n = 74) vs non (n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0. 8, 95%CI 0. 5-1. 3, p = 0. 35) or DHL vs DEL vs other (three-way p value, p = 0. 5).
Response rates and toxicities were similar among groups. Patients with DEL had the highest relapse rates post-CART, while DHL had the worst overall survival after CART relapse. In sum, our data support the notion that CART cell therapy can overcome the poor prognostic impact of DHL and DEL DLBCL in the relapsed/refractory setting.
Additionally, patients with DHL that relapse after CART have a very poor prognosis.
论文信息
- 作者
- Karmali R、Shouse G、Torka P、Moyo TK、Romancik J、Barta SK、Bhansali R、Cohen JB
- 单位
- Robert H Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA. Reem.Karmali@nm.org.United States
- 文献类型
- 多中心研究
- 期刊
- Blood cancer journal2025 Mar 26
- 原文标识
- PubMed 40140360 · DOI 10.1038/s41408-025-01250-8
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →